Ischemic Etiology And Clinical Outcomes Following Cardiac Resynchronization Therapy

Below is result for Ischemic Etiology And Clinical Outcomes Following Cardiac Resynchronization Therapy in PDF format. You can download or read online all document for free, but please respect copyrighted ebooks. This site does not host PDF files, all document are the property of their respective owners.

2017 Cardiology Clinical Trials - University of Pittsburgh

systolic dysfunction of either ischemic or non-ischemic etiology. Inclusion criteria: Age 18-80 with diagnosis of chronic HF of ischemic or non-ischemic etiology for at least six months before the initiation of screening procedures, NYHA Class II-III symptoms, on stable and optimally tolerated dosages of heart failure

Determinants of functional capacity after mitral valve

For the eligible portion of the population, clinical information was obtained through an outpatient clinic, and was 90% complete. Postoperative cardiac events were defined as the occurrence of death or cardiac-related hospitalization, as recommended in the American College of Cardiology/American Heart Association guidelines.22,23

Continued versus Suspended Cardiac Resynchronization Therapy

cardiac resynchronization therapy ( cRt) improves outcomes in heart failure patients with wide QRS complex. However, CRT management following continuous ow Left Ventricular Assist Device (LVAD) implant vary: some centers continue CRT while others turn o the left ventricular (LV) lead at LVAD implant.

Distinct trajectories of disease-specific health status in

benefit from cardiac rehabilitation in combination with psychological intervention. Keywords Heart failure Cardiac resynchronization therapy Health status KCCQ Trajectories Introduction Heart failure (HF) is a complex and debilitating clinical syndrome, characterized by symptoms of fatigue, dyspnea,

Outcomes of Cardiac Resynchronization Therapy With or Without

BACKGROUND Recent studies have cast doubt on the benefit of cardiac resynchronization therapy (CRT) with defi-brillation (CRT-D) versus pacing (CRT-P) for patients with nonischemic cardiomyopathy (NICM). Left ventricular myocardial scar portends poor clinical outcomes.

Predictors of Long-Term Adverse Outcomes in Elderly Patients

Outcomes The status of all patients was surveyed by June 2008 and the following information of the outcomes was obtained from the participating cardiologists by using a web-based EDC system: (1) all-cause death; (2) cardiac death, defined as death due to HF, myocardial infarction and other causes such as pulmonary

Machine learning-based risk model using 123I

(ICD) and cardiac resynchronization therapy (CRT) for patients at high risk of ArE and HFD, respectively, seem reasonable risk-based therapeutic interventions. This study was designed to establish a means of differentiating the probabilities of cardiac death due to ArE and HFD using a machine learning-based classifier

A multicenter prospective randomized controlled trial of

of cardiac resynchronization therapy guided by Mean age was 70.8 6 10.9 years and 54% had ischemic etiology. and better clinical outcomes is not clear. Small

The Association of a classical left bundle Branch Block

cardiac resynchronization therapy Kasper Emerek 1,2* , Daniel J. Friedman 1 , Peter L. Sørensen 3 , Steen M. Hansen 4 , Jacob M. Larsen 5 , Niels Risum 6 , Anna Margrethe Thøgersen 5 , Claus Graff 3 , Brett D. Atwater 1 , Joseph Kisslo 1 and Peter Søgaard 2,5

Atrial high rate episodes predict clinical outcome in

Keywords: cardiac resynchronization therapy, atrial fibrillation, atrial high rate episodes, device-diagnostics, long-term prognosis, mortality Introduction Cardiac resynchronization therapy (CRT) is a well-validated treatment option for patients with congestive heart failure (HF), widened QRS-complex and signs of electrical dyssynchrony during

Demographics, clinical characteristics, and outcomes among

Etiology and HF precipitating factors (Table 2, Fig. 3) The most common etiology of HF overall was ischemic heart disease; however, the prevalence differed signifi-cantly ranging from 72.5% in Alexandria to 40.9% in Upper Egypt (P < 0.01). The second most common etiology in Alexandria and Delta was dilated cardiomy-opathy (DCM).

Acute Ischemic Mitral Regurgitation and Cardiogenic Shock

heart failure providers. The role of oral medical therapy or cardiac resynchronization therapy is limited here. The choice comes down to mitral valve intervention and/or LVAD placement, and evidence remains scarce on the optimal treatment for ischemic MR in such a complex patient. If the surgical risk is reasonable, the patient could

-adrenergic receptor polymorphisms in susceptibility

HF patients showed the following characteristics: EF 35±9%, 69.9% male, age 59±13 years, 50.7% self-identified as black, 46% had ischemic etiology. The mean follow-up of 23 months showed 18 mortalities and 46 hospitalizations. The genotypes Glu27Glu (24.7 vs. 6.1%, P=0.0004) and Arg16Arg (72.6 vs.

Cardiac resynchronization therapy in continuous flow left

Introduction: Whether cardiac resynchronization therapy (CRT) continues to augment left ventricular remodeling in patients with the continuous-flow left ventricular assist device (cf-LVAD) remains unclear. Methods: We performed a systematic review and meta-analysis of all clinical studies examining the role of continued CRT in end-stage

Predictors of rhythm outcomes after cardiac resynchronization

and ventricular arrhythmias.1-3 Cardiac resynchronization therapy (CRT) has been shown to alleviate these effects and since HF patients today survive longer, CRT is increasingly being used in AF patients.4 However, the benefits of CRT therapy in AF patients are only com-parable to patients in sinus rhythm (SR), if AF patients preserve a high

Mechanical effects of left ventricular midwall fibrosis in

mural distribution following coronary artery territories were regarded as ischemic in etiology [4] and excluded. Those with epicardial, transmural or patchy fibrosis sug-gestive of other etiologies were also excluded. It is routine clinical practice at the two recruiting dedicated heart failure units to perform CMR as part of the diagnostic

Journal of Arrhythmia

tion Trial-Cardiac Resynchronization Therapy (MADIT-CRT) study, in which patients with ischemic cardiomyopathy and NYHA class I were enrolled in about 15% of total subjects [11].

Impact of Myocardial Scarring on Outcomes of Cardiac

Dec 12, 2011 treatment, 5-y mortality still approaches 50% (1). Cardiac resynchronization therapy (CRT) is a treatment option for advanced HF despite optimal medical therapy, reduced LV ejection fraction (EF), and wide QRS complex. Random-ized studies have demonstrated that CRT can improve car-diac function, clinical symptoms, quality of life, and even

Long‐Term Outcomes of Cardiac Resynchronization Therapy Using

decision. Patients underwent a clinical assessment on the day before implantation and at 1, 3, and every 6 months following device implantation. Clinical Perspective What Is New? † In recipients of cardiac resynchronization therapy, an apical left ventricular lead position was associated with better long-term cardiac survival than a nonapical

Narrowing filtered QRS duration on signal‐averaged

Cardiac resynchronization therapy (CRT) can decrease mortality and morbidity in congestive heart failure (HF) patients with impaired left ventricular (LV) function and cardiac dyssynchrony (Brignole et al., 2013). HF patients with nonischemic etiology, those with left bundle branch block (LBBB) morphology and those with wider QRS duration

l i n ic ment Journal of Clinical and Experimental al o l f a

Cardiac Resynchronization Therapy (CRT) has emerged as a highly effective treatment modality for patients with systolic heart failure and prolonged QRS duration. Meta-analysis has shown that CRT, in addition to optimal medical therapy, reduces mortality in patients with heart failure [1], improves symptoms, exercise tolerance and decreases


Sep 15, 2020 Despite the fact that cardiac resynchronization therapy functional class IV, ischemic etiology, atrial fi- Outcomes consisting of HF hospitalization and cardiac

RESEARCH Open Access Cardiac resynchronization therapy guided

deployment away from scarred myocardium results in a better clinical outcome after CRT. Pacing scarred myocardium was associated with the worst outcome, in terms of both pump failure and sudden cardiac death. Background Cardiac resynchronization therapy (CRT) is an estab-lished treatment for symptomatic patients with heart

Myocardial Strain Imaging

controlled trial that will evaluate clinical outcomes for patients who are monitored by myocardial strain imaging or conventional imaging. Patients with an abnormal test result will receive improved blood pressure and glucose control. Protective therapy with ACE inhibitors and beta blockers will be titrated to target dose.

RESEARCH ARTICLE Open Access Novel myocardial markers GADD45G

covery of cardiac function after optimal pharmacological or device therapy [2, 3]. This phenomenon, known as LV reverse remodeling (LVRR), is associated with im-proved clinical outcomes. Accordingly, several indices have been identified as predictors of LVRR and heart failure, including blood biomarkers like suppression of

660 Review Article Multimodality imaging assessment of mitral

Secondary MR is a powerful predictor of outcomes, such as all-cause mortality, heart transplant and/or heart failure hospitalization (5,17,53-55). In addition to the first line optimal guideline-directed medical therapy (GDMT) for heart failure, cardiac resynchronization therapy and/or

Sex Differences in Long-Term Outcomes With Cardiac

Key Words: cardiac resynchronization therapy with defibrillator † clinical outcomes † sex † implantable cardioverter-defibrillator † long-term survival † mild heart failure † mortality † QRS duration C ardiac resynchronization therapy with defibrillator (CRT-D) has been shown to be associated with significant

Outcomes of cardiac resynchronization therapy in patients

clinical outcomes including cardiac death, heart transplantation, and heart failure (HF)- Kim JS, Park S-J (2019) Outcomes of cardiac resynchronization therapy in patients with atrial

Cardiac Risk Factors and Non-invasive Cardiac Diagnosis-ECG

investigating cardiac resynchronization therapy in systolic dysfunction related chf I have received consulting fees and contracts from Boston Scientific President and Chief Scientific Officer of the CorVita Science Foundation (CSF), a nonprofit alliance of clinicians devoted to cardiovascular care, education and clinical collaboration

Implantable Cardioverter Defibrillator (ICD)

(unless patient is eligible to receive a combination cardiac resynchronization therapy ICD device) have had cardiac revascularization procedure in past 3 months (coronary artery bypass graft [CABG] or percutaneous transluminal coronary angioplasty [PTCA]) or are candidates for a cardiac revascularization procedure

Impact on Clinical Outcomes of Periodic Leg Movements During

PLM and clinical outcomes. In the univariable analysis, the presence of severe PLM was used as an independent variable along with the following baseline variables: age, sex, body mass index, ischemic etiology, presence or absence of AF, implantable cardioverter defibrillator, cardiac resynchronization therapy, LVEF, systolic and diastolic BP,

Assessment of the Role of Speckle Tracking Echocardiography

Cardiac resynchronization therapy (CRT) is now an established therapy for patients with advanced heart failure with prolonged QRS duration. Apart from clinical benefits, improvement of left ventricular (LV) systolic function and associated LV reverse remodeling has been reported. (3) Recently, improvement of

Use of Cardiac Resynchronization Therapy in the Medicare

search term cardiac resynchronization therapy or CRT or biventricular pacing , received from 01/22/2014 to 01/21/2015 and were conducted in those >≥18years of age A-2

Beta Blockers Up-Titration in Patients with Heart Failure

cardiac resynchronization therapy is not well known. In this study, we evaluate the possibility of increasing -blockers doses in an unselected cohort of heart failure reduced ejection patients after cardiac resynchronization therapy capable defibrillator system implantation and the correlation between -blockers treatments and clinical outcome.

2019 Cardiology Clinical Trials - University of Pittsburgh

pharmacogenomics-guided drug therapy individualization following PCI. We hypothesize that: targeted genetic variants are detectable in UPMC patients, point-of-care interventions can be accomplished, clinical outcomes are improved, and patients find these processes acceptable. PreCISE-Rx establishes to create a bio-bank to enable future research

Systematic Review for the 2018 ACC/AHA/HRS Guideline on the

May 26, 2017 8 cardiac resynchronization therapy/ or cardiac resynchronization therapy device/ (24429) 9 (Cardiac resynchronization therapy or Cardiac resynchronisation therapy or CRT or ((Biventricular or biv) and (pacing or pacemaker$ or pace-maker$ or paced)) or bivp).ab,kw,ti. (28965) 10 His bundle/ (3410)

Canadian Cardiovascular Society Guidelines on the Use of

the practical use of cardiac resynchronization therapy (CRT), beyond clinical trial inclusion/exclusion criteria, in a real-world population. The consensus panel consisted of experts in cardiac electrophysiology, heart failure (HF), cardiac surgery, cardiac imaging, general cardiology, internal medi-cine, knowledge translation, and health services.

The utility of echocardiographic right ventricular parameters

The Annals of Clinical and Analytical Medicine RV function and CRT response 554 Introduction Cardiac resynchronization therapy (CRT) is an established treat-ment for patients with systolic heart failure (HF) and ventricular electrical dyssynchrony [1,2]. Despite technological advances in device implantation and programming, nearly one-third of HF

Prediction of clinical outcome in patients treated with

Cardiac resynchronization therapy (CRT) is a well-validated treatment for morbidity and mortality reduction in select patients with heart failure [1 4]. However, non-response to cardiac resynchronization therapy (CRT) con-tinues to be a clinical challenge, and the cause is likely multifactorial [5]. It may involve one or several factors